MGlu 2/3 agonists
AssigneeEli Lilly and Company
InventorsStephen Richard Baker, Christopher David Beadle, Barry Peter Clark, James Allen Monn, Lourdes Prieto
Life of this patent
Estimating the term…
Abstract
The present invention provides novel mGlu2/3 agonists of the formula wherein R1, R2, and R3 are as defined herein, for use in the treatment of neurological or psychiatric disorders.
Claims35
A compound of Formula I
- wherein
- R1 is hydrogen, R2 is hydrogen, and R3 is hydrogen;
- R1 is hydrogen, R2 is (2S)-2-aminopropanoyl, and R3 is hydrogen;
- R1 is hydrogen, R2 is (2S)-2-amino-4-methylsulfanyl-butanoyl, and R3 is hydrogen;
- R1 is hydrogen, R2 is 2-aminoacetyl, and R3 is hydrogen;
- R1 is benzyl, R2 is hydrogen, and R3 is benzyl;
- or
- R1 is (2-fluorophenyl)methyl, R2 is hydrogen, and R3 is (2-fluorophenyl)methyl;
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound of Formula I
- wherein
- R1 is hydrogen, R2 is hydrogen, and R3 is hydrogen;
- R1 is hydrogen, R2 is (2S)-2-aminopropanoyl, and R3 is hydrogen;
- R1 is hydrogen, R2 is (2S)-2-amino-4-methylsulfanyl-butanoyl, and R3 is hydrogen;
- R1 is hydrogen, R2 is 2-aminoacetyl, and R3 is hydrogen;
- R1 is benzyl, R2 is hydrogen, and R3 is benzyl;
- or
- R1 is (2-fluorophenyl)methyl, R2 is hydrogen, and R3 is (2-fluorophenyl)methyl;
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
A method of treating a neurological disorder selected from the group consisting of persistent pain, neuropathic pain, chronic inflammatory pain, and visceral pain, comprising administering to a patient in need thereof an effective amount of a compound of Formula I
- wherein
- R1 is hydrogen, R2 is hydrogen, and R3 is hydrogen;
- R1 is hydrogen, R2 is (2S)-2-aminopropanoyl, and R3 is hydrogen;
- R1 is hydrogen, R2 is (2S)-2-amino-4-methylsulfanyl-butanoyl, and R3 is hydrogen;
- R1 is hydrogen, R2 is 2-aminoacetyl, and R3 is hydrogen;
- R1 is benzyl, R2 is hydrogen, and R3 is benzyl;
- or
- R1 is (2-fluorophenyl)methyl, R2 is hydrogen, and R3 is (2-fluorophenyl)methyl;
- or a pharmaceutically acceptable salt thereof.
A method of treating a psychiatric disorder selected from the group consisting of schizophrenia, bipolar disorder, generalized anxiety disorder, and post traumatic stress disorder, comprising administering to a patient in need thereof an effective amount of a compound of Formula I
- wherein
- R1 is hydrogen, R2 is hydrogen, and R3 is hydrogen;
- R1 is hydrogen, R2 is (2S)-2-aminopropanoyl, and R3 is hydrogen;
- R1 is hydrogen, R2 is (2S)-2-amino-4-methylsulfanyl-butanoyl, and R3 is hydrogen;
- R1 is hydrogen, R2 is 2-aminoacetyl, and R3 is hydrogen;
- R1 is benzyl, R2 is hydrogen, and R3 is benzyl;
- or
- R1 is (2-fluorophenyl)methyl, R2 is hydrogen, and R3 is (2-fluorophenyl)methyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.